I'm not sure why anyone would consider InMed exploring "several" biosynthetic pathways great progress for a company targeted to commercialize this year. And those cost models, you mean the ones that Mr. Adams reported to be ready to communicate to shareholders in Dec? It will be just another "couple weeks" into the summer and you'll still be waiting. Now if you said they're making great progress on continued delays we'd surely agree on that.
News 
Market Data 
Discover 
AI
